PremiumCompany AnnouncementsHLS Therapeutics Reports Mixed Q2 Results and Strategic Sales HLS Therapeutics Expands Vascepa Coverage in Canada HLS Therapeutics Schedules Q2 Financial Results Call PremiumCompany AnnouncementsHLS Therapeutics Announces Q1 2024 Financial Results HLS Therapeutics Showcases at Investor Conference HLS’s VASCEPA Shows Promise for Heart Disease Patients